Reported cash
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
Price chart
What changed?
No verified development in tracked sources.
Upcoming catalysts
Next verified event · Clinical readout window
ALN-2232 · clinical data · February 2027
obesity and weight management
Phase 1
Announced Oct 29, 2026 · Announced window
Official announcementSource wording
The Company now expects to announce clinical data from the Phase 2 trial of ALN-6400 in patients with hereditary hemorrhagic telangiectasia (HHT), as well as from the Phase 1 trial of ALN-2232 in obesity and weight management, in conjunction with its fourth quarter and full year 2026 earnings call in February 2027.
Clinical readout window
ALN-6400 · clinical data · February 2027
Announced Oct 29, 2026 · Announced window
Official announcementSource wording
The Company now expects to announce clinical data from the Phase 2 trial of ALN-6400 in patients with hereditary hemorrhagic telangiectasia (HHT), as well as from the Phase 1 trial of ALN-2232 in obesity and weight management, in conjunction with its fourth quarter and full year 2026 earnings call in February 2027.
Drug pipeline
0 programs · 0 verified studies
No verified studies linked yet.
95 unverified sponsor matches remain unlinked.
Verified timeline
0 recordsNo verified developments in tracked sources.